Detalles de la búsqueda
1.
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 2024 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38828933
2.
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Cancer
; 129(23): 3746-3760, 2023 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37622738
3.
Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1.
Haematologica
; 105(10): 2440-2447, 2020 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33054084
4.
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial.
Lancet
; 385(9980): 1873-83, 2015 May 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-25882396
5.
Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL.
Acta Oncol
; 55(9-10): 1115-1120, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27494089
6.
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.
Clin Cancer Res
; 29(17): 3340-3351, 2023 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37379430
7.
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
Lancet Haematol
; 10(10): e801-e812, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37793771
8.
Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.
Clin Cancer Res
; 25(7): 2058-2063, 2019 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30659024
9.
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
J Clin Oncol
; : JCO2018783118, 2018 Aug 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-30153097
10.
Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL.
Leuk Lymphoma
; 58(7): 1598-1606, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27830957
11.
Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.
Leuk Lymphoma
; 58(5): 1084-1093, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-27731748
12.
Assessment of the effect of ofatumumab on cardiac repolarization.
J Clin Pharmacol
; 55(1): 114-21, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25103870
13.
Identification of altered dipeptidyl-peptidase activities as potential biomarkers for unipolar depression.
J Affect Disord
; 151(2): 667-672, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23948634
14.
Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections.
PLoS One
; 5(2): e9166, 2010 Feb 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-20161799
15.
Fifteen years of env C2V3C3 evolution in six individuals infected clonally with human immunodeficiency virus type 1.
J Med Virol
; 79(11): 1629-39, 2007 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-17854039
Resultados
1 -
15
de 15
1
Próxima >
>>